Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy

Documenti analoghi

• Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
  di: Zain Abedali, et al.
  Pubblicazione: (2024)
• Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
  di: Umang Swami, et al.
  Pubblicazione: (2024)
• Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
  di: Fabio Matrone, et al.
  Pubblicazione: (2024)
• The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer
  di: Cem Onal, et al.
  Pubblicazione: (2024)
• Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
  di: Thomas Büttner, et al.
  Pubblicazione: (2024)